- Home
- SELF vs TCRX Comparison
SELF vs TCRX Comparison
Compare SELF & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SELF | TCRX |
|---|---|---|
| Founded | 1983 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.3M | 63.6M |
| IPO Year | 1997 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SELF | TCRX |
|---|---|---|
| Price | $5.08 | $1.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 23.9K | ★ 573.2K |
| Earning Date | 05-08-2026 | 03-04-2026 |
| Dividend Yield | ★ 5.71% | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $12,530,280.00 | $10,325,000.00 |
| Revenue This Year | $1.59 | N/A |
| Revenue Next Year | $1.62 | $69.75 |
| P/E Ratio | $33.80 | ★ N/A |
| Revenue Growth | 2.79 | ★ 266.65 |
| 52 Week Low | $4.73 | $0.88 |
| 52 Week High | $5.83 | $2.57 |
Technical Indicators
Market Signals| Indicator | SELF | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.80 | 45.07 |
| Support Level | $5.03 | $0.90 |
| Resistance Level | $5.22 | $1.24 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 42.11 | 14.00 |
Price Performance
Historical ComparisonAbout SELF Global Self Storage Inc.
Global Self Storage Inc is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops, and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible, and secure storage space for residential and commercial customers. It has one segment of Rental operations. Through its wholly-owned subsidiaries, the company owns and/or manages close to thirteen self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.